Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Merck Sharp & Dohme LLC
Emmanuel S Antonarakis; Se Hoon Park; Jeffrey C Goh; Sang Joon Shin; Jae Lyun Lee; Niven Mehra; Ray McDermott; Núria Sala-Gonzalez; Peter C Fong; Richard Greil; Margitta Retz; Juan Pablo Sade; Patricio Yanez; Yi-Hsiu Huang; Stephen D Begbie; Rustem Airatovich Gafanov; Maria De Santis; Eli Rosenbaum; Michael P Kolinsky; Felipe Rey; Kun-Yuan Chiu; Guilhem Roubaud; Gero Kramer; Makoto Sumitomo; Francesco Massari; Hiroyoshi Suzuki; Ping Qiu; Jinchun Zhang; Jeri Kim; Christian H Poehlein; Evan Y Yu